No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

byKathleen Lau

February 18, 2021

in StudyGraphics

#VisualAbstract: Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

RelatedReports

Nivolumab may be effective in platinum-resistant ovarian cancer

Surgery

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

August 9, 2026

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding

Chronic Disease

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

August 5, 2026

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Weekly Rewinds

2 Minute Medicine Rewind August 3rd, 2026

August 3, 2026

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

#VisualAbstract: Skin biopsy rates have disproportionately increased compared to cancer treatments between 1993-2016

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports